Palatin Technologies, Inc.
PTNHealthcareNASDAQBiotechnology · Last scanned Sep 3, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 2CONFIRMED
Multi-indicator alignment: When 2+ indicators show the same condition on the same day, Scanance highlights it. This is not a recommendation. It means the technical indicators are aligned.
Headquartered within the healthcare sector, Palatin Technologies, Inc. focuses on Biotechnology services and products. Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. The company carries a $22.8M market cap, placing it firmly in the micro-cap category. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
Market Cap
$22.8M
Beta
-0.10
P/E (TTM)
107.00
P/E (Fwd)
-5.28
EPS (TTM)
$0.12
EPS (Fwd)
$-2.43
ROE
-297.2%
ROA
-65.3%
Cash
$10.2M
Total Debt
$286,662
Free CF
-$13.7M
52W Change
28.2%
Annual Financials
Cash vs Debt
Where PTN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PTN finished 16.13% below its 150-day moving average ($15.31) and 20.00% below its 200-day moving average ($16.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTN overbought or oversold?
At the September 3, 2026 close, PTN's RSI(14) was 70.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $10.2M in cash and $287K in debt, PTN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$13.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -297.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.5M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Palatin Technologies, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, PTN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Palatin Technologies, Inc.'s trajectory.